$20.92
1.497.67%
At Close: -
$20.92
00.00%
After Hours: 4:56 PM EDT
15 minutes delayed
Edgewise Therapeutics
EWTXNASDAQ
Edgewise Therapeutics (NASDAQ:EWTX) Stock, Insider Trading Activity
Edgewise Therapeutics: Insider buying and selling updated today.
Institutional Shares Held
24.618M
Institutional Percentage Held
26.4%
| May 03, 2024 | John R Moore | GENERAL COUNSEL | 3.252K | $18.91 | -$36.99K | SELL-OPTIONS | ∞ | 3.252K | May 01 - May 02 | View |
| May 03, 2024 | R. Michael Carruthers | CHIEF FINANCIAL OFFICER | 3.051K | $18.91 | -$40.79K | SELL-OPTIONS | 9.48% | 35.23K | May 01 - May 02 | View |
| May 03, 2024 | Behrad Derakhshan | CHIEF BUSINESS OFFICER | 3.49K | $18.91 | -$32.49K | SELL-OPTIONS | 35.14% | 13.422K | May 01 - May 02 | View |
| May 03, 2024 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | 3.632K | $18.91 | -$29.80K | SELL-OPTIONS | 100.72% | 7.238K | May 01 - May 02 | View |
| May 03, 2024 | Donovan Joanne M | CMO | 6.735K | $18.91 | -$69.63K | SELL-OPTIONS | 51.17% | 19.897K | May 01 - May 02 | View |
| May 03, 2024 | Kevin Koch | PRESIDENT AND CEO | 7.265K | $18.91 | -$59.60K | SELL-OPTIONS | 21.61% | 40.888K | May 01 - May 02 | View |
| Feb 09, 2024 | John R Moore | GENERAL COUNSEL | 0 | $10.97 | -$539.22K | SELL-OPTIONS | 0.00% | 0 | Feb 07 - Feb 09 | View |
| Feb 09, 2024 | Behrad Derakhshan | CHIEF BUSINESS OFFICER | 0 | $10.98 | -$180.96K | SELL-OPTIONS | 0.00% | 7.02K | Feb 07 - Feb 09 | View |
| Jan 25, 2024 | R. Michael Carruthers | CHIEF FINANCIAL OFFICER | 0 | $8.85 | -$1.25M | SELL-OPTIONS | 0.00% | 29.024K | Jan 23 | View |
| Jan 25, 2024 | Peter A Thompson | DIRECTOR | 454.545K | $11.00 | $5.00M | BUY | 3.18% | 14.756096M | Jan 23 | View |
| Jan 25, 2024 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCOrbiMed Genesis GP LLC | DIRECTOR | 454.545K | $11.00 | $5.00M | BUY | 3.18% | 14.756096M | Jan 23 | View |
| Dec 28, 2023 | Fox Jonathan C | — | 10.857K | $9.30 | $100.96K | BUY | ∞ | 10.857K | Dec 26 | View |
| Dec 28, 2023 | John R Moore | GENERAL COUNSEL | -8.497K | $10.50 | -$89.22K | SELL | -100.00% | 0 | Dec 27 | View |
| Dec 28, 2023 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -172.585K | $9.33 | -$1.61M | SELL | -97.95% | 3.606K | Dec 26 | View |
| May 03, 2023 | Behrad Derakhshan | CHIEF BUSINESS OFFICER | 3.461K | $8.90 | -$15.56K | SELL-OPTIONS | 97.25% | 7.02K | May 01 - May 02 | View |
| May 03, 2023 | John R Moore | GENERAL COUNSEL | 3.311K | $8.90 | -$16.89K | SELL-OPTIONS | 101.75% | 6.565K | May 01 - May 02 | View |
| May 03, 2023 | R. Michael Carruthers | CHIEF FINANCIAL OFFICER | 3.872K | $8.90 | -$11.90K | SELL-OPTIONS | 31.60% | 16.126K | May 01 - May 02 | View |
| May 03, 2023 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | 3.606K | $8.90 | -$14.27K | SELL-OPTIONS | 2.09% | 176.191K | May 01 - May 02 | View |
| May 03, 2023 | Donovan Joanne M | CMO | 7.162K | $8.90 | -$28.98K | SELL-OPTIONS | 255.97% | 9.96K | May 01 - May 02 | View |
| May 03, 2023 | Kevin Koch | PRESIDENT AND CEO | 7.213K | $8.90 | -$28.52K | SELL-OPTIONS | 27.31% | 33.623K | May 01 - May 02 | View |
| Oct 05, 2022 | John R Moore | GENERAL COUNSEL | 0 | $5.84 | -$37.03K | SELL-OPTIONS | 0.00% | 3K | Oct 03 | View |
| Sep 16, 2022 | Peter A Thompson | DIRECTOR | 484.496K | $10.32 | $5.00M | BUY | 3.51% | 14.301551M | Sep 16 | View |
| Sep 16, 2022 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCOrbiMed Genesis GP LLC | DIRECTOR | 484.496K | $10.32 | $5.00M | BUY | 3.51% | 14.301551M | Sep 16 | View |
| Sep 16, 2022 | Novo Holdings AS | 10% OWNER | 484.496K | $10.32 | $5.00M | BUY | 8.67% | 6.071703M | Sep 14 | View |
| Sep 08, 2022 | John R Moore | GENERAL COUNSEL | 0 | $6.42 | -$42.47K | SELL-OPTIONS | 0.00% | 3K | Sep 06 | View |
| Aug 05, 2022 | John R Moore | GENERAL COUNSEL | 0 | $5.32 | -$73.60K | SELL-OPTIONS | 0.00% | 3K | Aug 03 | View |
| Jul 07, 2022 | John R Moore | GENERAL COUNSEL | 0 | $4.85 | -$64.93K | SELL-OPTIONS | 0.00% | 3K | Jul 05 - Jul 06 | View |
| Jun 21, 2022 | John R Moore | GENERAL COUNSEL | 0 | $4.26 | -$349.32K | SELL-OPTIONS | 0.00% | 3K | Jun 16 - Jun 21 | View |
| Jun 15, 2022 | John R Moore | GENERAL COUNSEL | 0 | $3.41 | -$141.01K | SELL-OPTIONS | 0.00% | 3K | Jun 13 - Jun 15 | View |
| Jun 10, 2022 | John R Moore | GENERAL COUNSEL | 0 | $3.58 | -$156.49K | SELL-OPTIONS | 0.00% | 3K | Jun 08 - Jun 10 | View |
| Jun 07, 2022 | John R Moore | GENERAL COUNSEL | 0 | $3.87 | -$225.64K | SELL-OPTIONS | 0.00% | 3K | Jun 03 - Jun 07 | View |
| May 20, 2022 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCOrbiMed Genesis GP LLC | DIRECTOR | 138K | $7.21 | $994.98K | BUY | 1.01% | 13.817055M | May 18 | View |
| May 20, 2022 | Peter A Thompson | DIRECTOR | 138K | $7.21 | $994.98K | BUY | 1.01% | 13.817055M | May 18 | View |
| May 18, 2022 | John R Moore | GENERAL COUNSEL | -10.8K | $7.42 | -$80.15K | SELL | -78.26% | 3K | May 16 | View |
| Nov 17, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -479 | $19.11 | -$9.16K | SELL | -100.00% | 0 | Nov 15 | View |
| Nov 12, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -69.74K | $19.91 | -$1.39M | SELL | -99.32% | 479 | Nov 09 - Nov 12 | View |
| Nov 08, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -29.451K | $19.82 | -$583.82K | SELL | -29.55% | 70.219K | Nov 04 - Nov 08 | View |
| Nov 03, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -44.172K | $17.88 | -$789.91K | SELL | -30.71% | 99.67K | Nov 01 - Nov 03 | View |
| Oct 18, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -7.182K | $18.17 | -$130.48K | SELL | -4.76% | 143.842K | Oct 14 - Oct 15 | View |
| Oct 13, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -1.27K | $18.02 | -$22.89K | SELL | -0.83% | 151.024K | Oct 11 | View |
| Oct 08, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -21.028K | $18.39 | -$386.74K | SELL | -12.13% | 152.294K | Oct 06 - Oct 08 | View |
| Oct 05, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -5.778K | $18.24 | -$105.41K | SELL | -3.23% | 173.322K | Oct 01 - Oct 05 | View |
| Sep 30, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -26.454K | $17.10 | -$452.48K | SELL | -12.87% | 179.1K | Sep 28 - Sep 29 | View |
| Sep 27, 2021 | Russell Alan J | CHIEF SCIENTIFIC OFFICER | -58.546K | $18.30 | -$1.07M | SELL | -22.17% | 205.554K | Sep 23 - Sep 27 | View |
| Mar 31, 2021 | Jonathan Root M.D. | DIRECTOR | 3.489168M | $16.00 | $250.00K | BUY | ∞ | 15.625K | Mar 30 | View |
| Mar 31, 2021 | Peter Thompson M.D. | DIRECTOR | 13.362135M | $16.00 | $5.75M | BUY | ∞ | 13.359456M | Mar 30 | View |
| Mar 31, 2021 | ORBIMED ADVISORS LLCOrbiMed Capital GP VI LLCOrbiMed Genesis GP LLC | DIRECTOR | 13.362135M | $16.00 | $5.75M | BUY | ∞ | 13.359456M | Mar 30 | View |
| Mar 31, 2021 | Peter Haahr Chief Financial Officer of Novo Holdings A/S | 10% OWNER | 5.587207M | $16.00 | $10.00M | BUY | ∞ | 5.587207M | Mar 30 | View |
| Mar 30, 2021 | James FlynnDeerfield Mgmt IV LPDEERFIELD MANAGEMENT COMPANY LP SERIES CDeerfield Private Design Fund IV LP | 10% OWNER | 3.933137M | $16.00 | $10.00M | BUY | ∞ | 3.933137M | Mar 30 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.